Hypomagnesemia in persons with type 1 diabetes: associations with clinical parameters and oxidative stress.

BACKGROUND: Among persons with type 1 diabetes mellitus (T1DM) low concentrations of magnesium have been reported. Previous (small) studies also suggested a relation of hypomagnesemia with (poor) glycaemic control and complications. We aimed to investigate the magnitude of hypomagnesemia and the associations between magnesium with parameters of routine T1DM care in a population of unselected outpatients. METHODS: As part of a prospective cohort study, initially designed to measure quality of life and oxidative stress, data from 207 patients with a mean age of 45 [standard deviation (SD) 12] years, 58% male, diabetes duration 22 [interquartile range (IQR) 16, 31] years and glycated haemoglobin (HbA1c) of 60 (SD 11) mmol/mol [7.6 (SD 1.0)%] were examined. Hypomagnesemia was defined as a concentration below <0.7 mmol/l. RESULTS: Mean magnesium concentration was 0.78 (SD 0.05) mmol/l. A deficiency was present in 4.3% of participants. Among these persons, mean concentration was 0.66 (SD 0.03) mmol/l. There was no correlation between magnesium and HbA1c at baseline (r = -0.014, p = 0.843). In multivariable analysis, free thiols (reflecting the degree of oxidative stress) were significantly and negatively associated with magnesium concentrations. CONCLUSION: In this cohort of T1DM outpatients, the presence of hypomagnesemia was infrequent and, if present, relative mild. Magnesium was not associated with glycaemic control nor with presence of micro- and macrovascular complications. Although these results need confirmation, in particular the negative association of magnesium with free thiols, this suggests that hypomagnesemia is not a relevant topic in routine care for people with T1DM.

Destabilization dynamics of clay and acid-free polymers of ferric and magnesium salts in AMD without pH adjustment.

The physicochemical treatment was employed to treat acid mine drainage (AMD) in the removal of turbid materials using clay only (exp A) and a combination of clay, FeCl3 and Mg(OH)2 (exp B) to form a polymer. A 5 g sample of clay (bentonite) was added to 1.2 L of AMD and treated in a jar test at 250 rpm for 2 min and reduced to 100 rpm for 10 min. A 200 mL sub-sample from the 1.2 L mother liquor was poured into five 500 mL glass beakers, and 20 mL dosages of a polymer of 0.1 M Fe(3+) in (FeCl3) and 0.1 M Mg(2+) in (Mg(OH)2) was added to the beakers. The samples were allowed to settle for 1 h, after which the supernatant was analyzed for pH, total suspended solids (TSS), dissolved oxygen (DO) and oxidation-reduction potential (ORP) (exp A). A similar set of experiments was conducted where 200 mL of the AMD sample was poured into 500 mL glass beakers and (20-60 mL) dosages of a combination of 5 g clay, 0.1 M Fe(3+) (FeCl3) and Mg(2+) (Mg(OH)2) polymer was added and similar mixing, settling time and measurements were conducted (exp B). The polymers used in exp A exhibited TSS removal efficiency (E%) which was slightly lower compared with the polymer used in exp B, above 90%. Clay has a high TSS removal efficiency in the treatment of the AMD, indicating that adsorption was a predominant process in exps A and B. The scanning electron microscope (SEM) micrographs of the AMD sludge of both exps A and B, with a rigid and compacted structure consisting of dense flocs surrounded by the smaller flocs bound together, corroborate the fact that adsorption is a predominant process.

Volume control in treatment-resistant congestive heart failure: role for peritoneal dialysis.

Chronic congestive heart failure (HF) has a rising prevalence and increasing impact on health care systems. Current treatment consists of diuretics, renin-angiotensin-aldosterone system blockers, and restriction of salt and fluids. This strategy is often hampered by a drop in effective circulating volume and hence renal perfusion and function, triggering harmful counter regulatory mechanisms. Slow ultrafiltration by peritoneal dialysis (PD) might be an effective treatment strategy to relieve fluid overload without compromising cardiac output and thereby renal function. In this review, we discuss the (patho)physiological mechanisms of the cardiorenal interaction and the current literature on PD strategies in congestive HF.

Current concepts in the management of diabetic nephropathy.

Although much progress has been made in slowing the progression of diabetic nephropathy, renal dysfunction and development of end-stage renal disease (ESRD) remain major concerns in diabetes. In addition, diabetic patients with microalbuminuria have an increased cardiovascular mortality. Therefore, new treatment modalities or strategies are needed to prevent or slow the progression of diabetic nephropathy and prevent cardiovascular disease in diabetes. In this review we describe current concepts in pathophysiology, treatment goals and we discuss future developments in the treatment of diabetic nephropathy. Common risk factors for diabetic nephropathy and its progression are longer duration, poor glycaemic control, hypertension and the presence of albuminuria. Available treatment options, especially renin-angiotensin aldosterone system (RAAS) blockade, but also better blood pressure and blood glucose control, decrease the incidence of cardiovascular disease and renal disease in diabetes. It is important that treatment goals are tailored to the individual patient with individual treatment goals of glycaemic control and blood pressure, depending on age, type of diabetes and diabetes duration. Aggressive treatment of glucose control and blood pressure might not always be best practice for every patient. Since the proportion of ESRD due to diabetic nephropathy remains high, optimisation of RAAS blockade is advocated and can be achieved by adequate sodium restriction and/or diuretic treatment. Moreover, aldosterone blockade might be a valuable strategy, which has potency to slow the progression of diabetic renal disease. Other possible future interventions are under investigation, but large clinical trials have to be awaited to confirm the safety and efficacy of these drugs.

Feasibility of mitral valve surgery using minimal extracorporeal circulation.

AIM: Using minimal extracorporeal circulation (MECC) in isolated coronary artery bypass grafting or aortic valve replacement has been proven to be safe, feasible and superior compared to standard cardiopulmonary bypass (CPB) in terms of postoperative complications, total hospital stay and blood product transfusions. This feasibility study evaluates the clinical outcomes of mitral valve surgery performed with MECC. METHODS: From March 2006 to January 2011, seventy-five patients who underwent mitral valve surgery performed with MECC (n=75) in our institution were retrospectively evaluated. Demographic characteristics, operative data and clinical outcomes were collected in a prospectively designed database. RESULTS: The mean age was 68.8 ± 10.2 years with a EuroSCORE of 7.0 ± 2.3. Thirty-seven patients had a moderate left ventricular function (with a range of 30-40%). All patients except two had severe mitral valve incompetence (MI). Surgery was successful in all procedures. The mean duration of surgery was 210 ± 44 min (range 118-356 min). The mean CPB time was 128 ± 30 (range 67-249) min. The cross-clamp time was 99 ± 26 (range 48-205) min. There were no intraoperative perfusion problems or airlocks reported. The mean intensive care unit (ICU) length of stay was two days. Subsequent analysis showed a first postoperative haemoglobin value of 9.4 g/dL ± 1.7. There were no peroperative neurological complications. One patient developed an ischaemic cerebrovascular accident (CVA) on the forth postoperative day due to inadequate anticoagulation. Other postoperative complications included eight patients with pneumonia, one superficial wound infection, temporary renal insufficiency in two patients and four patients needed re-exploration for excessive postoperative leakage. Overall in-hospital mortality was four percent. CONCLUSION: Our results show, for the first time, that isolated or combined mitral valve surgery using MECC is feasible and safe.

The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria.

BACKGROUND: Overt proteinuria is a strong risk factor for thromboembolism, owing to changes in the levels of various coagulation proteins and urinary antithrombin loss. The described coagulation disturbances in these patients are based on outdated studies conducted primarily in the 1970s and 1980s. Whether these coagulation disturbances resolve with antiproteinuric therapy has yet to be studied. METHODS: A total of 32 patients with overt proteinuria (median, 3.7 g day(-1) ; interquartile range, 1.5-5.6) were enrolled in this intervention crossover trial designed to assess optimal antiproteinuric therapy with sodium restriction, losartan, and diuretics. Levels of various procoagulant and anticoagulant proteins, and parameters of two thrombin generation assays (calibrated automated thrombogram [CAT] and prothrombin fragment 1 + 2) were compared between the placebo period and the maximum antiproteinuric treatment period. As a secondary analysis, coagulation measurements of the placebo period in these patients were compared with those of 32 age-matched and sex-matched healthy controls. RESULTS: Median proteinuria was significantly lower during the maximum treatment period (median, 0.9 g day(-1) ; interquartile range, 0.6-1.4; P < 0.001) than during the placebo period. Similarly, levels of various liver-synthesized procoagulant and anticoagulant proteins, activated protein C resistance and prothrombin fragment 1 + 2 levels were significantly lower during the maximum treatment period than during the placebo period. However, von Willebrand factor and factor VIII levels were similar. On the basis of the higher levels of procoagulant proteins (fibrinogen, FV, FVIII, and von Willebrand factor) and both thrombin generation assays, patients were substantially more prothrombotic than healthy controls (P < 0.004). CONCLUSIONS: Antiproteinuric therapy ameliorates the prothrombotic state. Proteinuric patients are in a more prothrombotic state than healthy controls.

Continuous surveillance of lower limb perfusion during aortic surgery with near-infrared spectroscopy: a pilot study.

BACKGROUND: Near-infrared spectroscopy (NIRS) is a noninvasive technique that allows continuous monitoring of the regional hemoglobin oxygen saturation (rSO(2)) index. We evaluated its application to survey perioperative lower limb perfusion. METHODS: A total of 10 patients (7 men, aged 71) were monitored during abdominal surgery for aortic aneurysms. The rSO(2) index was measured at the M gastrocnemius (optode 1) and at the dorsum of the foot (optode 2). RESULTS: Mean baseline rSO(2) values for optodes 1 and 2 were 67 and 66, respectively. After clamping the aorta or iliacofemoral arteries, rSO(2) dropped to 32 for optode 1 (P<.0001) and to 27 for optode 2 (P<.0001). After declamping, rSO(2) increased to 74 for optode 1 (P=.0012 vs baseline) and also to 74 for optode 2 (P=.0018 vs baseline). CONCLUSION: Near-infrared spectroscopy is an easily applicable, noninvasive tool for continuous surveillance of lower extremity perfusion during aortic reconstruction.

Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.

OBJECTIVE: Dyslipidemia contributes to increased cardiovascular risk in nephrotic syndrome. We questioned whether reduction in proteinuria not only lowers low-density lipoprotein cholesterol (LDL-C), but also high-density lipoprotein cholesterol (HDL-C) and cholesteryl ester transfer protein (CETP) mass and whether changes in HDL-C were related to changes in plasma adiponectin. METHODS: Thirty-two non-diabetic proteinuric patients (12 on statin therapy), were followed during two double blind 6-week periods of placebo and treatment (low sodium + 100mg losartan + 25 mg hydrochlorothiazide). RESULTS: With placebo HDL-C was lower but LDL-C and CETP were not different in proteinuric patients compared with matched controls. LDL-C, HDL-C and CETP decreased upon proteinuria reduction. The decrease in LDL-C correlated with the drop in CETP and the degree of proteinuria reduction. HDL-C also decreased in proportion to proteinuria lowering. Individual changes in HDL-C were correlated with changes in adiponectin. CONCLUSION: LDL-C lowering upon robust reduction of proteinuria may be affected by changes in plasma CETP mass, but this treatment also decreases HDL-C in relation to the degree of proteinuria reduction. This adverse effect on HDL-C may in part be attributable to changes in adiponectin.

Sarcoidosis mimicking metastatic disease: a case report and review of the literature.

Osseous and in particular vertebral sarcoidosis is exceedingly rare and a difficult diagnosis to establish because it may simulate many diseases, including even metastatic malignancy. we present a patient with lesions in bones, lungs and lymph nodes, mimicking the presence of extensive metastatic disease. our case emphasises the importance of histological evidence before the diagnosis of osseous sarcoidosis can be made with confidence.

Mini extracorporeal circuit for coronary artery bypass grafting: initial clinical and biochemical results: a comparison with conventional and off-pump coronary artery bypass grafts concerning global oxidative stress and alveolar function.

BACKGROUND: The new concept of mini-extracorporeal circulation (MECC) for coronary artery bypass grafts (MCABG) consists of minimal priming volume, a heparin-coated closed circuit, a centrifugal pump, active drainage, blood cardioplegia and a cell-saving device. The potential organ protective effect of this technique during CABG is unknown. Initial clinical outcomes, oxidative stress, alveolar shunting and need for blood transfusion were investigated for MCABG patients. Sub-sets of these data were compared to outcomes of matched groups of patients operated conventionally (CCABG) and off-pump (OPCAB). METHODS: Data of 184 patients were gathered and analysed from a prospective observational database system. This database consists of the initial experience with the first 114 MCABG operations. Of these, the clinical outcome was investigated. In a subset of 60 MCABGs, need for transfusion was monitored and compared to 60 CCABGs. Serum concentrations of malondialdehyde (MDA), allantoin/urate ratios, shunt fractions and lung epithelium-specific proteins (CC16) were measured as biomarkers of damage during MCABG, CCABG and OPCAB (n =30). RESULTS: Patient groups were similar concerning age, risk and number of distal anastomoses. Clinical outcomes are shown for MCABGs only. During MCABG, need for transfusion was significantly reduced compared to CCABG (p < 0.001). Serum concentrations of MDA and allantoin/urate ratios showed significantly reduced oxidative stress during MCABG compared to CCABG. During MCABG, F-shunts were reduced shortly after surgery. Increased concentrations of pneumoprotein CC16 were measured during CCABG compared to MCABG (data submitted). CONCLUSION: Short-term clinical outcomes of MCABG patients are satisfactory. Compared to CCABG the need for transfusion is significantly reduced when a MECC is used. Oxidative stress parameters show a tendency towards improved global organ protection compared to CCABG. F-shunt fractions and CC16 concentrations suggest reduced alveolar damage during MCABG. In a prospective study, the protective effect of mini-CABG has to be confirmed.

Bilateral antegrade selective cerebral perfusion during surgery on the proximal thoracic aorta.

OBJECTIVE: To assess risk factors for hospital death and neurologic outcome after surgery on the proximal thoracic aorta using moderate hypothermic circulatory arrest and bilateral antegrade selective cerebral perfusion. METHODS: From October 1995 through June 1999, 163 patients with a mean age of 63+/-11 years underwent surgery using bilateral antegrade selective cerebral perfusion. Degenerative aneurysms (55%) and acute type A dissection (28%) were the predominant indications for operation. Forty-six (28%) operations were considered as emergency procedure. Twenty-four (15%) procedures were reoperations. RESULTS: Mean ASCP time was 48+/-20 min. Hospital mortality was 8.6% (n=14; 70% confidence limit (CL): 6.4-10.8%). Univariate risk factors for hospital mortality were acute type A dissection (P=0.003), central neurologic damage <24 h before the operation (P=0.000), preoperative hemodynamic instability (P=0.034), and rethoracotomy for any cause (P=0.036). Logistic regression analysis identified central neurologic damage <24 h (P=0.006, odds ratio 14) as an independent risk factor. Temporary neurologic damage occurred in 3.8% (n=6; 70% CL: 2.3-5.3%) of patients. Logistic regression analysis indicated preoperative hemodynamic instability (P=0.003, odds ratio 13) as an independent risk factor. Perioperative permanent central neurologic damage was reported in another 3.8% (n=6; 70% CL: 2.3-5.3%) patients. Acute type A dissection (P=0.018, odds ratio 8) and the non-use of a midline sternotomy (P=0.049, odds ratio 8) were retained as independent risk factors. CONCLUSION: Hospital mortality and perioperative neurologic complications are not significantly influenced by the duration of antegrade selective cerebral perfusion. Overall complication rate is low.